Search
Sparsentan
go.drugbank.com/drugs/DB12548ApprovedInvestigationalFurthermore, it is the first non-immunosuppressive therapy for the reduction of proteinuria in IgAN.[L45315] The use of sparsentan may cause hepatotoxicity and embryo-fetal toxicity. … [L45300,L45315] In September 2024, it was granted full approval for an expanded indication.
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesInsulin lispro
go.drugbank.com/drugs/DB00046ApprovedInvestigationalInsulin also inhibits hepatic glucose production, enhances protein synthesis, and inhibits lipolysis and proteolysis among many other functions. … Absorption of glucose into cells allows for its transformation into glycogen or fat for storage.
Mixtures: HUMALOG MIX 25 SUSPENSION FOR INJECTION 100 iu/ml, HUMALOG MIX 25 SUSPENSION FOR INJECTION 100 iu/mlCategories: Insulins and Analogues for Injection, Fast-Acting, Cytochrome P-450 CYP1A2 InducersPinaverium
go.drugbank.com/drugs/DB09090ApprovedInvestigationalIt is shown to relieve GI spasm and pain, transit disturbances and other symptoms related to motility disorders [A19697] and may be considered as effective first-lline therapy for patients with irritable … Pinaverium is a spasmolytic agent used for functional gastrointestinal disorders. It is a quaternary ammonium compound that acts as an atypical calcium antagonist to restore normal bowel function.
Categories: Drugs for Functional Gastrointestinal Disorders, Cytochrome P-450 SubstratesBalsam of Peru
go.drugbank.com/drugs/DB11482ApprovedNutraceuticalVet approved[F117] Under the FDA, balsam of Peru is considered as an inactive ingredient to be used for approved drug products[L2878] as well as an approved food additive under the categorization of generally recognized
Mixtures: Keloid Healer Synergy for treatment of keloidsDefactinib
go.drugbank.com/drugs/DB12282ApprovedInvestigational[L53208,A273943] Defactinib was approved by the US FDA in May 2025 in a co-package alongside [avutometinib] (called Avmapki Fakzynja) for the treatment of recurrent KRAS-mutated low-grade serous ovarian … [L53198,L53208] FAK is important for the integrin-mediated activation of several downstream signal transduction pathways, including those involving RAS/MEK/ERK and PI3K/Akt, and its upregulation is a key
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 InducersNedosiran
go.drugbank.com/drugs/DB17635ApprovedInvestigationalNedosiran is an RNA interference targeting hepatic lactate dehydrogenase, the enzyme responsible for the conversion of glyoxylate to oxalate. … [A261690] Oxalate, particularly calcium oxalate, precipitation is the main cause of kidney stones formation; therefore, blocking the production of oxalate can help alleviate renal symptoms.
Buntanetap
go.drugbank.com/drugs/DB15317InvestigationalBuntanetap (previously known as Posiphen) is under investigation in clinical trial NCT02925650 (Safety, Tolerability, PK and PD of Posiphen® in Subjects With Early Alzheimer's Disease).
Chlorpromazine
go.drugbank.com/drugs/DB00477ApprovedInvestigationalVet approvedChlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup.
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesCangrelor
go.drugbank.com/drugs/DB06441ApprovedInvestigationalCangrelor is an intravenous, direct-acting, reversible P2Y12 inhibitor for patients undergoing percutaneous coronary intervention (PCI) who have not been yet treated by oral P2Y12 inhibitors. … Cangrelor was approved by the FDA in June 2015 for intravenous application.
Categories: Purinergic P2 Receptor Antagonists, Purinergic P2Y Receptor AntagonistsOxamniquine
go.drugbank.com/drugs/DB01096ApprovedAn anthelmintic with schistosomicidal activity against Schistosoma mansoni, but not against other Schistosoma spp. … Oxamniquine causes worms to shift from the mesenteric veins to the liver where the male worms are retained; the female worms return to the mesentery, but can no longer release eggs.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 Inhibitors